Cargando…
Efficacy and Safety of Low-Dose Protamine in Reducing Bleeding Complications during TAVI: A Propensity-Matched Comparison
Objectives: We aimed to evaluate the efficacy and safety of low-dose protamine in reducing access site-related complications during Transcatheter Aortic Valve Implantation (TAVI) as compared to full-dose protamine. Background: Access site-related complications represent an independent predictor of p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342582/ https://www.ncbi.nlm.nih.gov/pubmed/37445282 http://dx.doi.org/10.3390/jcm12134243 |
_version_ | 1785072533426405376 |
---|---|
author | Kneizeh, Kinan Milzi, Andrea Vogt, Felix Witte, Klaus Marx, Nikolaus Lehrke, Michael Almalla, Mohammad Schröder, Jörg |
author_facet | Kneizeh, Kinan Milzi, Andrea Vogt, Felix Witte, Klaus Marx, Nikolaus Lehrke, Michael Almalla, Mohammad Schröder, Jörg |
author_sort | Kneizeh, Kinan |
collection | PubMed |
description | Objectives: We aimed to evaluate the efficacy and safety of low-dose protamine in reducing access site-related complications during Transcatheter Aortic Valve Implantation (TAVI) as compared to full-dose protamine. Background: Access site-related complications represent an independent predictor of poor outcomes of TAVI. Data regarding heparin reversal with protamine and the dosage needed to prevent bleeding complications are scarce among patients undergoing TAVI. Methods: A total of 897 patients were retrospectively included in the study. Patients who underwent percutaneous coronary intervention within 4 weeks before or concomitantly with TAVI (n = 191) were given 0.5 mg protamine for each 100 units of unfractionated heparin. All other patients (n = 706) were considered as a control group and 1 mg protamine for each 100 units of heparin was administered. Results: The combined intra-hospital endpoint of death, life-threatening major bleeding, and major vascular complications were significantly more frequent in patients receiving low-dose protamine [29 (15.2%) vs. 50 (7.1%), p < 0.001]. After propensity matching (n = 130 for each group) for relevant clinical characteristics including anti-platelet therapy [19 (14.6%) vs. 6 (4.6%), p = 0.006], low-dose protamine predicted the combined endpoint (OR 3.54, 95%-CI 1.36–9.17, p = 0.009), and even in multivariable analysis, low-dose protamine continued to be a predictor of the combined endpoint in the matched model (OR 3.07, 95%-CI 1.17–8.08, p = 0.023) alongside baseline hemoglobin. Conclusions: In this propensity-matched retrospective analysis, a low-dose protamine regime is associated with a higher rate of major adverse events compared to a full-dose protamine regime following transfemoral TAVI. |
format | Online Article Text |
id | pubmed-10342582 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103425822023-07-14 Efficacy and Safety of Low-Dose Protamine in Reducing Bleeding Complications during TAVI: A Propensity-Matched Comparison Kneizeh, Kinan Milzi, Andrea Vogt, Felix Witte, Klaus Marx, Nikolaus Lehrke, Michael Almalla, Mohammad Schröder, Jörg J Clin Med Article Objectives: We aimed to evaluate the efficacy and safety of low-dose protamine in reducing access site-related complications during Transcatheter Aortic Valve Implantation (TAVI) as compared to full-dose protamine. Background: Access site-related complications represent an independent predictor of poor outcomes of TAVI. Data regarding heparin reversal with protamine and the dosage needed to prevent bleeding complications are scarce among patients undergoing TAVI. Methods: A total of 897 patients were retrospectively included in the study. Patients who underwent percutaneous coronary intervention within 4 weeks before or concomitantly with TAVI (n = 191) were given 0.5 mg protamine for each 100 units of unfractionated heparin. All other patients (n = 706) were considered as a control group and 1 mg protamine for each 100 units of heparin was administered. Results: The combined intra-hospital endpoint of death, life-threatening major bleeding, and major vascular complications were significantly more frequent in patients receiving low-dose protamine [29 (15.2%) vs. 50 (7.1%), p < 0.001]. After propensity matching (n = 130 for each group) for relevant clinical characteristics including anti-platelet therapy [19 (14.6%) vs. 6 (4.6%), p = 0.006], low-dose protamine predicted the combined endpoint (OR 3.54, 95%-CI 1.36–9.17, p = 0.009), and even in multivariable analysis, low-dose protamine continued to be a predictor of the combined endpoint in the matched model (OR 3.07, 95%-CI 1.17–8.08, p = 0.023) alongside baseline hemoglobin. Conclusions: In this propensity-matched retrospective analysis, a low-dose protamine regime is associated with a higher rate of major adverse events compared to a full-dose protamine regime following transfemoral TAVI. MDPI 2023-06-24 /pmc/articles/PMC10342582/ /pubmed/37445282 http://dx.doi.org/10.3390/jcm12134243 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kneizeh, Kinan Milzi, Andrea Vogt, Felix Witte, Klaus Marx, Nikolaus Lehrke, Michael Almalla, Mohammad Schröder, Jörg Efficacy and Safety of Low-Dose Protamine in Reducing Bleeding Complications during TAVI: A Propensity-Matched Comparison |
title | Efficacy and Safety of Low-Dose Protamine in Reducing Bleeding Complications during TAVI: A Propensity-Matched Comparison |
title_full | Efficacy and Safety of Low-Dose Protamine in Reducing Bleeding Complications during TAVI: A Propensity-Matched Comparison |
title_fullStr | Efficacy and Safety of Low-Dose Protamine in Reducing Bleeding Complications during TAVI: A Propensity-Matched Comparison |
title_full_unstemmed | Efficacy and Safety of Low-Dose Protamine in Reducing Bleeding Complications during TAVI: A Propensity-Matched Comparison |
title_short | Efficacy and Safety of Low-Dose Protamine in Reducing Bleeding Complications during TAVI: A Propensity-Matched Comparison |
title_sort | efficacy and safety of low-dose protamine in reducing bleeding complications during tavi: a propensity-matched comparison |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342582/ https://www.ncbi.nlm.nih.gov/pubmed/37445282 http://dx.doi.org/10.3390/jcm12134243 |
work_keys_str_mv | AT kneizehkinan efficacyandsafetyoflowdoseprotamineinreducingbleedingcomplicationsduringtaviapropensitymatchedcomparison AT milziandrea efficacyandsafetyoflowdoseprotamineinreducingbleedingcomplicationsduringtaviapropensitymatchedcomparison AT vogtfelix efficacyandsafetyoflowdoseprotamineinreducingbleedingcomplicationsduringtaviapropensitymatchedcomparison AT witteklaus efficacyandsafetyoflowdoseprotamineinreducingbleedingcomplicationsduringtaviapropensitymatchedcomparison AT marxnikolaus efficacyandsafetyoflowdoseprotamineinreducingbleedingcomplicationsduringtaviapropensitymatchedcomparison AT lehrkemichael efficacyandsafetyoflowdoseprotamineinreducingbleedingcomplicationsduringtaviapropensitymatchedcomparison AT almallamohammad efficacyandsafetyoflowdoseprotamineinreducingbleedingcomplicationsduringtaviapropensitymatchedcomparison AT schroderjorg efficacyandsafetyoflowdoseprotamineinreducingbleedingcomplicationsduringtaviapropensitymatchedcomparison |